Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
GSK To Collaborate On Insomnia Drug
July 21, 2008
| A version of this story appeared in
Volume 86, Issue 29
GlaxoSmithKline will collaborate with Actelion for the development and commercialization of Actelion's almorexant, an orexin receptor antagonist in Phase III clinical development for insomnia. Under the terms of the deal, GSK will make an up-front payment of $149 million for worldwide codevelopment and co-commercialization rights to the drug exclusive of Japan. GSK will also make up to $411 million in milestone payments for successful development and commercialization of almorexant for insomnia. Successful commercialization of the drug for insomnia and two other potential indications could boost the value of the collaboration to $3.3 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X